in

Stocks to buy in 2025: Dr Lal PathLabs, Aurobindo Pharma among top 5 stocks which could rally 14-28% in 12 months – Brokerage Recommendations

Maintain Outperform | Target Rs 7,928 | LTP Rs 6,154 | Upside 28%

Macquarie has maintained an Outperform rating on Polycab India with a target price of Rs 7,928, reflecting a potential upside of 28% from the current market price of Rs 6,154.

(Disclaimer: Recommendations, suggestions, views, and…

Read More

What do you think?

Written by pulseadmin

Leave a Reply

Your email address will not be published. Required fields are marked *

GIPHY App Key not set. Please check settings

Adani Energy Shares May Rise 67%, Says Investec As It Maintains ‘Buy’ Post Q3 Earnings

Stock Market Sectors: Stock market update: Fertilisers stocks down as market rises